---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-097180"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-08-14T20:16:35+00:00"
generated_at: "2026-08-14T20:25:19.719046+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q2 2026 net loss $3.9M, cash down to $0.2M; advances NurOwn Phase 3b

## Summary
- Q2 2026 net loss $3.9M vs $2.9M in Q2 2025; EPS -$0.35 vs -$0.34.
- Cash, equivalents, restricted cash $0.2M at June 30, 2026, down from $1.03M a year earlier.
- G&A jumped to $2.7M from $1.5M; R&D was ~$1.0M vs $1.1M.
- Phase 3b ENDURANCE trial of NurOwn in ALS planned for ~200 patients under FDA SPA; Peter Pitts named Executive Chairman.
- Raised $400k in May 2026 private placement; H1 2026 total capital ~$2.4M.

## SEC filing metadata
- accession: 0001104659-26-097180
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-08-14T20:16:35+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/0001104659-26-097180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-097180
- JSON: https://secwatch.observer/filing/0001104659-26-097180.json
- Plain text: https://secwatch.observer/filing/0001104659-26-097180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.